Sutter Health

Department Chair

Site Lead and Psychiatrist

Self-Management of Depression

Depression is a complex illness, which presents in a myriad of ways and almost 60-70% people treated with antidepressants fail to achieve a symptom-free state when first treated with these medications. The treatment of depression cannot be pigeon-holed into one or two kinds of treatment modalities. Self-management is increasingly becoming the standard of care in people with long-standing medical conditions. Self-management puts one in the driver’s seat with regards to making choices regarding one’s health. However, treatment of depression has lagged behind in incorporating the concept of self-management with the most popular self-help paradigm on depression focusing mostly on cognitive-behavioral approaches. Self-management goes beyond the narrow perspective of self-help and addresses life style changes, social relationships, communication, problem-solving, and also includes elements of wellness and recovery.

Author and Blogger

Kaiser Permanente

Senior Physician

County of Humboldt

Medical Director

ProMedica

UPMC

Resident Physician

Central Institute of Psychiatry

Mahatma Gandhi Institute of Medical Sciences

House Officer

Harpreet S. Duggal, MD, FAPA, is a board-certified psychiatrist and an international expert on self-management of depression. He has practiced psychotherapy and psychopharmacology for over 20 years and has authored over one hundred articles in scientific journals. He is also a bestselling author of books on depression. Check out his blog on evidence-based strategies for self-management of depression and lifestyle psychiatry. The content on this platform or other social media sites should not be construed as treatment advice or a substitute for it.

Harpreet Duggal, MD, FAPA

Cold Spring Venture Advisors

Providing product and clinical development and strategic advisory services to life science companies.

Principal

Aldeyra Therapeutics

Clinical stage company developing novel compounds to target aldehydes implicated in the pathogenesis of inflammatory conditions and orphan diseases; (NASDAQ:ALDX)

Member, Board of Directors (Chair, Nominating & Governance Committee; member, Audit Committee)

Cleveland Diagnostics, Inc.

Developer of cancer diagnostics based on protein structural vartiability as detected by solvent interaction analysis

Chairman, Board of Directors

Short Wave Pharma

Short Wave Pharma Inc. is an Israel-based biopharmaceutical company developing novel
formulations of psilocybin combined with additional APIs and customized delivery methods to
provide significant medical benefits for patients suffering from mental health disorders,
neurodegenerative diseases, chronic pain, and potentially other medical conditions where
psilocybin is known to have a positive effect.

1CellBio Inc.

1CellBiO Inc. is a leading single-cell analysis company commercializing the open, flexible and cost-effective inDropTM instrument for single cell, high resolution whole transcriptome profiling with unparalleled data quality.

Member Board Of Directors

Weill Cornell Medicine

Visiting Assistant Professor of Pathology and Laboratory Medicine

Member, Scientific Advisory Committee, Daedalus Fund for Innovation

Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology.  Aclaris is focused on large, underserved market segments with no FDA-approved medications or where treatment gaps exist.

Executive Vice President, Clinical Development

Sentien Biotechnologies, Inc.

Sentien's lead product, the Sentinel™, will actively treat acute kidney injury (acute renal failure) patients during continuous renal replacement therapy by supplementing patient blood with Mesenchymal Stromal Cell-derived secretions, a mixture of natural anti-inflammatory and trophic molecules that can attenuate the immune dysfunction of acute renal failure while promoting a tissue repair response. The company has developed proprietary Mesenchymal Stromal Cell compositions and GMP manufacturing methods to advance combination products that unlock the potential of cell therapy.

Chief Medical Officer (interim)

Cytrellis Biosystems, Inc.

Cytrellis is a clinical stage company developing a new class of aesthetic medical devices

taplio

The Battle

Harpreet Duggal, MD, FAPA

Ben Bronstein, MD

Followers

Posts

Engagements

Likes

Ready to grow your LinkedIn presence?